biib091

BIIB091 is a potent, selective, orally active, and reversible small molecule inhibitor of Bruton's tyrosine kinase (BTK), developed by Biogen for the treatment of multiple sclerosis (MS)[1][2][3][5][6]. By inhibiting BTK—a non-receptor tyrosine kinase involved in B cell and myeloid cell signaling—BIIB091 aims to reduce inflammation and immune-mediated damage in the central nervous system characteristic of MS[2][3][6]. The drug has demonstrated high selectivity and potency in preclinical studies by sequestering BTK's active site residue TYR-551 into an inactive conformation[1][2]. It is currently being evaluated in phase 2 clinical trials for relapsing forms of MS[4][5][6].

Other names

(r)-1-(tert-butyl)-n-(8-(2-((1-methyl-1h-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1h-benzo[c]azepin-5-yl)-1h-1,2,3-triazole-4-carboxamide